BRIEF-Priovant Announces Positive Phase 2 Results For Brepocitinib In Cutaneous Sarcoidosis (Cs)

Roivant Sciences Ltd. +0.93% Pre

Roivant Sciences Ltd.

ROIV

29.39

29.39

+0.93%

0.00% Pre

- Priovant:

  • PRIOVANT ANNOUNCES POSITIVE PHASE 2 RESULTS FOR BREPOCITINIB IN CUTANEOUS SARCOIDOSIS (CS)

  • PRIOVANT - BREPOCITINIB WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS

  • PRIOVANT: PLANS TO PROGRESS CS TO A PIVOTAL PROGRAM WITH A PHASE 3 STUDY STARTING IN CALENDAR YEAR 2026 FOLLOWING ENGAGEMENT WITH FDA

Source text: ID:nGNX6Tw17l

Further company coverage: ROIV.O